7358 related articles for article (PubMed ID: 17718062)
21. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
22. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
23. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
24. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer.
Sakurai Y; Kawai H; Iwano S; Ito S; Ogawa H; Naganawa S
J Med Imaging Radiat Oncol; 2013 Jun; 57(3):297-305. PubMed ID: 23721138
[TBL] [Abstract][Full Text] [Related]
25. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
26. PET and PET-CT. State of the art and future prospects.
Fanti S; Franchi R; Battista G; Monetti N; Canini R
Radiol Med; 2005; 110(1-2):1-15. PubMed ID: 16163136
[TBL] [Abstract][Full Text] [Related]
27. Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI.
Ruf J; Lopez Hänninen E; Oettle H; Plotkin M; Pelzer U; Stroszczynski C; Felix R; Amthauer H
Pancreatology; 2005; 5(2-3):266-72. PubMed ID: 15855825
[TBL] [Abstract][Full Text] [Related]
28. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET.
Antoch G; Saoudi N; Kuehl H; Dahmen G; Mueller SP; Beyer T; Bockisch A; Debatin JF; Freudenberg LS
J Clin Oncol; 2004 Nov; 22(21):4357-68. PubMed ID: 15514377
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT.
Tsuji K; Kishi S; Tsuchida T; Yamauchi T; Ikegaya S; Urasaki Y; Fujiwara Y; Ueda T; Okazawa H; Kimura H
J Magn Reson Imaging; 2015 Jun; 41(6):1601-7. PubMed ID: 25111444
[TBL] [Abstract][Full Text] [Related]
30. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
31. Improved detection of breast cancer on FDG-PET cancer screening using breast positioning device.
Kaida H; Ishibashi M; Fujii T; Kurata S; Ogo E; Tanaka M; Hayabuchi N
Ann Nucl Med; 2008 Feb; 22(2):95-101. PubMed ID: 18311533
[TBL] [Abstract][Full Text] [Related]
32. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
33. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
[TBL] [Abstract][Full Text] [Related]
34. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
35. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer.
Qu X; Huang X; Yan W; Wu L; Dai K
Eur J Radiol; 2012 May; 81(5):1007-15. PubMed ID: 21354739
[TBL] [Abstract][Full Text] [Related]
36. Application of PET and PEt/CT imaging for cancer screening.
Chen YK; Ding HJ; Su CT; Shen YY; Chen LK; Liao AC; Hung TZ; Hu FL; Kao CH
Anticancer Res; 2004; 24(6):4103-8. PubMed ID: 15736459
[TBL] [Abstract][Full Text] [Related]
37. The detection rates and tumor clinical/pathological stages of whole-body FDG-PET cancer screening.
Ono K; Ochiai R; Yoshida T; Kitagawa M; Omagari J; Kobayashi H; Yamashita Y
Ann Nucl Med; 2007 Jan; 21(1):65-72. PubMed ID: 17373338
[TBL] [Abstract][Full Text] [Related]
38. PET/CT in oncology: a major technology for cancer care.
Ell PJ
Chang Gung Med J; 2005 May; 28(5):274-83. PubMed ID: 16086542
[TBL] [Abstract][Full Text] [Related]
39. PET and cancer screening.
Yasuda S; Ide M
Ann Nucl Med; 2005 May; 19(3):167-77. PubMed ID: 15981668
[TBL] [Abstract][Full Text] [Related]
40. Ten-year prospective evaluation of whole-body cancer screening with multiple modalities including [
Nishizawa S; Kojima S; Okada H; Shinke T; Torizuka T; Teramukai S; Fukushima M
Ann Nucl Med; 2020 May; 34(5):358-368. PubMed ID: 32200511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
